Product Program year 2025 Source: CMS Open Payments

Dysport

Drug Neurology

NDC 15054-0500-1

Open in the dashboard

General payments

$5,964,929

20,396 payments

Research payments

$24,059,866

17,570 payments

Through program year 2025, $5,964,929 in general payments and $24,059,866 in research payments were reported against Dysport (Neurology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

14 rows
Year Kind Amount Payments
2025 General $1,240,222 4,835
2025 Research $7,961,380 7,901
2024 General $1,141,327 4,176
2024 Research $7,225,392 6,318
2023 General $1,127,189 3,632
2023 Research $2,966,349 1,866
2022 General $697,798 2,496
2022 Research $1,182,560 560
2021 General $494,303 1,342
2021 Research $851,650 183
2020 General $521,700 1,023
2020 Research $937,930 249
2019 General $742,389 2,892
2019 Research $2,934,605 493

Breakdown

Who paid General payments · program years 2019–2025
  1. Ipsen Biopharmaceuticals, Inc $4,808,286 19,872 payments
  2. Ipsen Innovation $782,549 327 payments
  3. Ipsen Pharma SAS $189,220 146 payments
  4. Ipsen Biopharm Limited $102,286 24 payments
  5. Ipsen Bioscience Inc $82,588 27 payments
Top recipients General payments · program year 2025
  1. Monica Verduzco-Gutierrez Brain Injury Medicine · San Antonio, TX $107,828 9% · 53 payments
  2. Michael Saulino Physical Medicine & Rehabilitation · Elkins Park, PA $95,075 8% · 59 payments
  3. Jose Urquidez Physical Medicine & Rehabilitation · Austin, TX $87,335 7% · 61 payments
  4. Laxman Bahroo Neurology · Washington, DC $77,504 6% · 45 payments
  5. Shivani Gupta Physical Medicine & Rehabilitation · Oak Lawn, IL $72,919 6% · 49 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Physical Medicine & Rehabilitation $651,151 55% · 496 practitioners
  2. Neurology Psychiatry & Neurology $300,582 25% · 525 practitioners
  3. Brain Injury Medicine Physical Medicine & Rehabilitation $108,803 9% · 10 practitioners
  4. Pediatric Rehabilitation Medicine Physical Medicine & Rehabilitation $32,160 3% · 36 practitioners
  5. Dermatology $30,009 3% · 1 practitioner

The top 5 of 75 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. Texas $246,487 20% · 250 recipients
  2. Pennsylvania $130,170 10% · 145 recipients
  3. Wisconsin $115,305 9% · 15 recipients
  4. Michigan $102,786 8% · 100 recipients
  5. New York $85,918 7% · 167 recipients

The top 5 of 51 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

1,106

Prescriptions dispensed, refills included

Drug cost

$1,850,963

Paid at the pharmacy, in all

Prescribers

40

With 11 or more claims of it

Medicare Part D drugs matched to DYSPORT, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Dysport Abobotulinumtoxina Same name 40 1,106 $1,850,963

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 40 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Daniel Tanenbaum Physical Medicine and Rehabilitation MA 71 $136,146 $79
Judith Gooch Physical Medicine and Rehabilitation UT 63 $127,442 $25,019
Mitchell Paulin Physical Medicine and Rehabilitation PA 62 $126,105 $102
Jose Cabassa Neurology NY 56 $95,690 $65
Bharathy Sundaram Neurology TX 51 $78,482 $50

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 40 with Patron

Given in the clinic

Part B · billing code
Medicare Part B billing codes matched to DYSPORT
Billing code Providers Services Paid by Medicare
Injection, abobotulinumtoxina, 5 units J0586 72 812,876 $5,183,255

Drugs given by a clinician are billed to Medicare Part B, not Part D. The product is tied to a billing code through the NDC on CMS's crosswalk, which was published for a later quarter than the payments, so a code that changed in between can be missed. Providers with fewer than 11 patients for the code are not published. Medicare's payment here is what it paid for the services, to the billing practice.

20,396 general · 17,570 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record